Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Physiomics ( (GB:PYC) ) has provided an announcement.
Physiomics plc has secured a follow-on contract with a UK-based biotech client specializing in AI-driven drug development. This contract involves updating a model with clinical data from a Phase 1 study to aid in clinical dosing strategy decisions, utilizing Physiomics’ Virtual Tumour platform. The project, valued at approximately £38,000, highlights the company’s growing influence in model-informed dose optimization in oncology.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, focusing on developing new therapeutics and personalized medicine solutions. The company leverages expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Their proprietary Virtual Tumour technology has been instrumental in informing the development of over 100 commercial projects for clients including Merck KGaA, Astellas, and Bicycle Therapeutics.
Average Trading Volume: 5,315,419
Technical Sentiment Signal: Strong Sell
Current Market Cap: £1.39M
For an in-depth examination of PYC stock, go to TipRanks’ Overview page.